{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:52Z","timestamp":1791410812272,"version":"4.3.3"},"reference-count":0,"publisher":"Pakistan Medical Association","issue":"4","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pak Med Assoc"],"abstract":"<jats:p>Immunotherapy related adverse events are commonly seen with immune check point inhibitors therapy. We report the case of a 40-year-old female diagnosed with stage IVB endometroid grade III endometrial cancer, on pembrolizumab immunotherapy, an anti-programmed-death-receptor-1 (PD-1) antibody. Patient was referred for 18F-FDG PET\/CT for restaging. 18F-FDG PET\/CT demonstrated diffuse increased FDG uptake throughout the body of the pancreas associated with fat stranding in the peripancreatic region, suggestive of pembrolizumab-induced pancreatitis. The diagnosis was confirmed by elevated amylase and lipase levels. Immune-related adverse events are frequently identified on 18F-FDG PET-CT, which may lead to early diagnosis, close clinical follow-up, and appropriate clinical management of immune-related adverse events.\r\nKey Words: 18F-FDG PET\/CT; pembrolizumab; pancreatitis; anti-programmed-death-receptor-1 (PD-1) antibody<\/jats:p>","DOI":"10.47391\/jpma.24-31","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T05:40:07Z","timestamp":1711431607000},"page":"825-826","source":"Crossref","is-referenced-by-count":2,"title":["Anti-programmed-death-receptor-1 (PD-1) antibody (Pembrolizumab) induced pancreatitis diagnosed on 18F-FDG PET\/CT"],"prefix":"10.47391","volume":"74","author":[{"family":"Sharjeel Usmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anjali Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Khulood Al Riyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Raza Sayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vipin V Jayakrishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26547","published-online":{"date-parts":[[2024,3,20]]},"container-title":["Journal of the Pakistan Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/download\/20590\/3133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/download\/20590\/3133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T05:40:07Z","timestamp":1711518007000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/view\/20590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,25]]}},"URL":"https:\/\/doi.org\/10.47391\/jpma.24-31","relation":{},"ISSN":["0030-9982"],"issn-type":[{"value":"0030-9982","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}